Research library

B

grade

GLP-1RA initiation may be associated with a lower likelihood of starting antidepressants and medications for substance use disorder, but further research is needed to clarify these associations.

aSR: 0.85; 95% CI: 0.76-0.94 for antidepressants initiation

summary

C

grade

This study presents a novel microsphere formulation of exenatide with promising stability and controlled release characteristics, but clinical relevance remains to be established.

Drug loading up to 4.7% w/w.

summary

B

grade

Exenatide has the highest reported rate of skin and injection-site reactions among GLP-1 receptor agonists, with 53.1% of reports indicating such issues.

53.1% of skin and injection-site reports for exenatide.

summary

C

grade

Semaglutide showed potential in preventing fentanyl seeking behavior in rats, but further research is needed to determine its relevance for human opioid use disorder treatment.

All doses of semaglutide fully prevented drug- and stress-induced reinstatement of fentanyl seeking.

summary

D

grade

GLP-1 receptor agonists may slow gastric emptying but do not significantly increase aspiration risk during endoscopy. Continue therapy with dietary and procedural precautions.

Aspiration rates during colonoscopy are approximately 0.01%-0.05%.

summary

B

grade

Clinicians should monitor for GERD symptoms in patients on GLP-1 RAs, particularly in the elderly, but exenatide may pose a lower risk.

Exenatide showed an inverse association in FAERS (ROR, 0.60; 95% CI, 0.46 to 0.77).

summary

B

grade

This study maps safety signals for GLP-1 therapies like exenatide but does not estimate incidence or causality. It's a tool for prioritizing safety concerns, not for clinical risk assessment.

243,114 GLP-1 primary-suspect case-product records within 8,995,547 background reports.

summary

B

grade

The study identifies potential safety signals for GLP-1 RAs, notably gastrointestinal and psychiatric effects, but these findings are preliminary and require further investigation.

544 PT-class pairs met the ≥3-of-4 signal criterion.

summary

A

grade

In adolescents with obesity, semaglutide appears to have the largest impact on weight loss, while exenatide may reduce systolic blood pressure, but the evidence is limited and indirect.

Exenatide 20 µg SC was associated with a reduction in systolic blood pressure of -6.64 mmHg, 95% CI -13.22 to -0.17.

summary

A

grade

Selected pharmacological interventions may improve body composition outcomes in acquired hypothalamic obesity, but the evidence is limited and of low certainty.

Not reported in abstract.

summary

B

grade

Semaglutide may be associated with better kidney outcomes compared to other GLP-1 receptor agonists, but no differences were found for the primary kidney outcome.

HR, 0.81 [95% CI, 0.70-0.93] for reduced risk of death with semaglutide compared to dulaglutide.

summary

A

grade

GLP-1 receptor agonists may reduce major adverse cardiovascular events and all-cause mortality by 11% in adults with type 2 diabetes and cardiovascular disease, based on high-certainty evidence from randomized trials.

11% reduction in major adverse cardiovascular events (hazard ratio: 0.89, 95% CI: 0.83-0.96)

summary

D

grade

Tirzepatide showed a significant reduction in fat mass compared to placebo, but it also decreased lean body mass, which could be a concern for overall health.

-10.70 kg fat mass reduction for tirzepatide vs placebo, 95% CI: -13.42 to -7.99.

summary

D

grade

Semaglutide and phentermine-topiramate appear to be effective adjuncts to lifestyle changes for managing obesity in children and adolescents, while the specific impact of exenatide remains less clear.

Not reported in abstract.

summary

B

grade

Semaglutide and liraglutide show higher psychiatric ADR reporting, suggesting the need for careful monitoring of patients using these GLP-1 RAs.

Semaglutide ROR 1.55; 95% CI 1.50–1.59.

summary

B

grade

Exenatide shows a lower disproportionality in impaired gastric emptying reports compared to other GLP-1 RAs, but the findings are descriptive and not indicative of clinical risk.

Exenatide PRR 4.7; 136/52,308

summary

B

grade

The study identifies a disproportionate reporting signal for impaired gastric emptying across GLP-1 RAs, particularly for semaglutide products, but does not establish causality.

Ozempic PRR 109.1; Rybelsus 66.4.

summary

D

grade

Not reported in abstract.

summary

B

grade

GLP-1 receptor agonists were associated with lower rates of hospitalizations for alcohol use disorder during treatment and shortly after stopping, but the benefits for substance use disorder were not consistent.

GLP-1 exposure associated with lower rates of alcohol use disorder hospitalizations (RR 0.55, 95% CI 0.43-0.70).

summary

A

grade

Short-term meal replacement therapy in adolescents with severe obesity showed a significant reduction in BMI and liver fat, but most participants still had metabolic dysfunction at the end of the study.

Mean absolute decrease in BMI of 5.6% [-2.23 kg/m²; 95% CI: -2.45, -2.02; p < 0.001]

summary